Tumor-suppressive miR-218-5p inhibits cancer cell proliferation and migration via EGFR in non-small cell lung cancer.
作者： Kegan Zhu , Hanying Ding , Wengong Wang , Zhicong Liao , Zheng Fu
关键词:
摘要: Lung cancer remains the leading cause of cancer-related death worldwide, and non-small cell lung (NSCLC) accounts for approximately 80% cases. Recently, microRNAs (miRNAs) have been consistently demonstrated to be involved in NSCLC act as either tumor oncogenes or suppressors. In this study, we identified a specific binding site miR-218-5p 3'-untranslated region epidermal growth factor receptor (EGFR). We further experimentally validated direct regulator EGFR. also an inverse correlation between EGFR protein levels tissue samples. Moreover, that plays critical role suppressing proliferation migration cells probably by Finally, examined function vivo revealed exerts anti-tumor effect negatively regulating xenograft mouse model. Taken together, results study highlight important regulation may open new avenues future therapies.
sci-hub.st 参考文章(43)
Y Yarden, The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. European Journal of Cancer. ,vol. 37, pp. 3- 8 ,(2001) , 10.1016/S0959-8049(01)00230-1
David P Bartel, MicroRNAs: Genomics, Biogenesis, Mechanism, and Function Cell. ,vol. 116, pp. 281- 297 ,(2004) , 10.1016/S0092-8674(04)00045-5
Conor E. Steuer, Suresh S. Ramalingam, Targeting EGFR in lung cancer: Lessons learned and future perspectives. Molecular Aspects of Medicine. ,vol. 45, pp. 67- 73 ,(2015) , 10.1016/J.MAM.2015.05.004
Mukesh Kumar, Vinicius Ernani, Taofeek K. Owonikoko, Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. Molecular Aspects of Medicine. ,vol. 45, pp. 55- 66 ,(2015) , 10.1016/J.MAM.2015.06.009
Pasqualina Giordano, Anna Manzo, Agnese Montanino, Raffaele Costanzo, Claudia Sandomenico, Maria Carmela Piccirillo, Gennaro Daniele, Nicola Normanno, Guido Carillio, Gaetano Rocco, Roberto Bianco, Francesco Perrone, Alessandro Morabito, Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors. Critical Reviews in Oncology Hematology. ,vol. 97, pp. 143- 151 ,(2016) , 10.1016/J.CRITREVONC.2015.08.016
Rodrigo Dienstmann, Pablo Martinez, Enriqueta Felip, Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer Oncotarget. ,vol. 2, pp. 165- 177 ,(2011) , 10.18632/ONCOTARGET.245
Andreas Gschwind, Oliver M. Fischer, Axel Ullrich, The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature Reviews Cancer. ,vol. 4, pp. 361- 370 ,(2004) , 10.1038/NRC1360
Alessandro Russo, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, Antonio Picone, Giuseppa Ferraro, Mariangela Zanghì, Giuseppe Toscano, Antonio Giordano, Vincenzo Adamo, A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives Oncotarget. ,vol. 6, pp. 26814- 26825 ,(2015) , 10.18632/ONCOTARGET.4254
Nancy E. Hynes, Heidi A. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer. ,vol. 5, pp. 341- 354 ,(2005) , 10.1038/NRC1609
Johannes S. de Jong, Paul J. van Diest, Paul van der Valk, Jan P. A. Baak, Expression of growth factors, growth‐inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis The Journal of Pathology. ,vol. 184, pp. 53- 57 ,(1998) , 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7